Christian Kersten

  • PhD
 

Publications 2018

Fey P, Chartomatsidou R, Kiefer W, Mottram JC, Kersten C, Schirmeister T (2018)
New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8
Eur J Med Chem, 156, 587-597
DOI 10.1016/j.ejmech.2018.07.012, PubMed 30029081

Mikkelsen HET, Vassbakk-Brovold K, Antonsen AJ, Berntsen S, Kersten C, Fegran L (2018)
Cancer Patients' Long-term Experiences of Participating in a Comprehensive Lifestyle Intervention Study While Receiving Chemotherapy
Cancer Nurs (in press)
DOI 10.1097/NCC.0000000000000650, PubMed 30312192

Vassbakk-Brovold K, J Antonsen A, Berntsen S, Kersten C, Fegran L (2018)
Experiences of Patients With Breast Cancer of Participating in a Lifestyle Intervention Study While Receiving Adjuvant Chemotherapy
Cancer Nurs, 41 (3), 218-225
DOI 10.1097/NCC.0000000000000476, PubMed 28221215

Publications 2017

Rohde G, Kersten C, Vistad I, Mesel T (2017)
Spiritual Well-being in Patients With Metastatic Colorectal Cancer Receiving Noncurative Chemotherapy: A Qualitative Study
Cancer Nurs, 40 (3), 209-216
DOI 10.1097/NCC.0000000000000385, PubMed 27101099

Vassbakk-Brovold K, Berntsen S, Fegran L, Lian H, Mjåland O, Mjåland S, Nordin K, Seiler S, Kersten C (2017)
Lifestyle changes in cancer patients undergoing curative or palliative chemotherapy: is it feasible?
Acta Oncol, 57 (6), 831-838
DOI 10.1080/0284186X.2017.1413247, PubMed 29239243

Publications 2016

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2016)
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723

Køstner AH, Kersten C, Löwenmark T, Ydsten KA, Peltonen R, Isoniemi H, Haglund C, Gunnarsson U, Isaksson B (2016)
The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker
J Surg Oncol, 114 (7), 895-899
DOI 10.1002/jso.24415, PubMed 27696432

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Vassbakk-Brovold K, Kersten C, Fegran L, Mjåland O, Mjåland S, Seiler S, Berntsen S (2016)
Cancer patients participating in a lifestyle intervention during chemotherapy greatly over-report their physical activity level: a validation study
BMC Sports Sci Med Rehabil, 8, 10
DOI 10.1186/s13102-016-0035-z, PubMed 27099757

Publications 2015

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fosså SD, Guren MG (2015)
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575

Mikkelsen HE, Brovold KV, Berntsen S, Kersten C, Fegran L (2015)
Palliative Cancer Patients' Experiences of Participating in a Lifestyle Intervention Study While Receiving Chemotherapy
Cancer Nurs, 38 (6), E52-8
DOI 10.1097/NCC.0000000000000235, PubMed 25730593

Pfeiffer P, Sorbye H, Qvortrup C, Karlberg M, Kersten C, Vistisen K, Lindh B, Bjerregaard JK, Glimelius B (2015)
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group
Clin Colorectal Cancer, 14 (3), 170-6
DOI 10.1016/j.clcc.2015.03.002, PubMed 25956187

Vassbakk-Brovold K, Berntsen S, Fegran L, Lian H, Mjåland O, Mjåland S, Seiler S, Kersten C (2015)
Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?
PLoS One, 10 (7), e0131355
DOI 10.1371/journal.pone.0131355, PubMed 26176950

Publications 2014

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH (2014)
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
BMC Cancer, 14, 340
DOI 10.1186/1471-2407-14-340, PubMed 24884501

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E (2014)
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer
J Clin Oncol, 32 (34), 3848-57
DOI 10.1200/JCO.2014.56.9327, PubMed 25366688

Publications 2013

Cameron MG, Kersten C, Guren MG, Fosså SD, Vistad I (2013)
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801

Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG (2013)
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692

Kersten C, Cameron MG, Mjåland S (2013)
Erratum to "Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series" [Scand. J. Pain 4 (2013) 3-7]
Scand J Pain, 4 (2), 125
DOI 10.1016/j.sjpain.2013.02.001, PubMed 29913890

Kersten C, Cameron MG, Mjåland S (2013)
Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain-A case series
Scand J Pain, 4 (1), 3-7
DOI 10.1016/j.sjpain.2012.11.011, PubMed 29913887

Kersten C, Cvancarova M, Mjåland S, Mjåland O (2013)
Does in-house availability of multidisciplinary teams increase survival in upper gastrointestinal-cancer?
World J Gastrointest Oncol, 5 (3), 60-7
DOI 10.4251/wjgo.v5.i3.60, PubMed 23671732

Kersten C, Louhimo J, Ålgars A, Lahdesmaki A, Cvancerova M, Stenstedt K, Haglund C, Gunnarsson U (2013)
Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer
Acta Oncol, 52 (8), 1691-8
DOI 10.3109/0284186X.2013.835494, PubMed 24102179

Publications 2012

Kersten C, Cameron MG (2012)
Cetuximab alleviates neuropathic pain despite tumour progression
BMJ Case Rep, 2012
DOI 10.1136/bcr.12.2011.5374, PubMed 22707700

Kersten C, Cameron MG, Oldenburg J (2012)
Truth in hope and hope in truth
J Palliat Med, 15 (1), 128-9
DOI 10.1089/jpm.2011.0209, PubMed 22268412

Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH (2012)
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
BMC Cancer, 12, 534
DOI 10.1186/1471-2407-12-534, PubMed 23167843

Kleist B, Xu L, Kersten C, Seel V, Li G, Poetsch M (2012)
Single nucleotide polymorphisms of the adult intestinal stem cell marker Lgr5 in primary and metastatic colorectal cancer
Am J Transl Res, 4 (3), 279-90
PubMed 22937206

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B (2012)
Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study
BMC Cancer, 12, 616
DOI 10.1186/1471-2407-12-616, PubMed 23259667

Publications 2011

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Cameron MG, Kersten C, van Helvoirt R, Rohde G, Fosså SD, Vistad I (2011)
Patient reported outcomes of symptoms and quality of life among cancer patients treated with palliative pelvic radiation: a pilot study
BMC Res Notes, 4, 252
DOI 10.1186/1756-0500-4-252, PubMed 21777440

Kleist B, Xu L, Li G, Kersten C (2011)
Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer
Int J Clin Exp Pathol, 4 (4), 327-35
PubMed 21577318

Publications 2007

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
Eur J Immunol, 37 (10), 2937-48
DOI 10.1002/eji.200636759, PubMed 17899540

Publications 2006

Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
Exp Hematol, 34 (1), 72-81
DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393

Publications 2005

Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
BMC Immunol, 6, 9
DOI 10.1186/1471-2172-6-9, PubMed 15877825

Publications 2004

Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
Cancer Immunol Immunother, 53 (12), 1119-26
DOI 10.1007/s00262-004-0558-0, PubMed 15185015

Page visits: 24